InpharmD™





Add Drug Information Pharmacists

Without Adding FTEs

So you can practice at top of license.

Get Started Free

Trusted by 20,000+ clinical pharmacists.

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?


Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


More than 30 of the world's best health systems hire an InpharmD™ virtual DI pharmacist, yielding:


168,476

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

should tamiflu be offered to critically ill patients. Please evaluate most recent study REMAP-CAP and other studies
What is the evidence behind cranberry and preventing UTI
What is the best alternate treatment for latent syphilis other than Penicillin g benzathine
Is there evidence for use of tebipenem in non-UTI indications?
Please review literature for incidence of bloodstream infections in oncology patients on TPN and data comparing infec...

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:zophia@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines, which predate the 2026 REMAP-CAP trial, recommend oseltamivir for hospitalized patients with severe influenza, emphasizing initiation as soon as possible, preferably within 48 hours of symptom onset. Following REMAP-CAP, UK guidance continues to recommend oseltamivir as first-line treatment for critically ill patients, while Australian guidance strongly recommends against its use in critically...

A 2026 Centers for Disease Control and Prevention (CDC) clinician summary recommends initiating oral or enterically administered oseltamivir as soon as possible in all hospitalized patients with suspected or confirmed influenza, without awaiting laboratory confirmation; observational evidence indicates that benefit is greatest with early treatment but may persist when treatment is initiated more than 48 hours after symptom onset. At the time, no sufficiently powered, randomized, placebo-controlled trials of neuraminidase inhibitor monotherapy had been completed in hospitalized patients; however, observational studies have associated treatment with shorter hospitalization and reduced risks of intensive care unit (ICU) transfer, invasive mechanical ventilation, or death, although some studies have not demonstrated a mortality reduction. Standard-dose oseltamivir achieves therapeutic concentrations in critically ill adults, including limited data involving administration through gastri...

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

should tamiflu be offered to critically ill patients. Please evaluate most recent study REMAP-CAP and other studies

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. March 10, 2026. Accessed August 17, 2026.
[2] World Health Organization (WHO). Clinical practice guidelines for influenza. September 12, 2024. Accessed August 17, 2026.
[3] UK Health Security Agency. Guidance on Use of Antiviral Agents for the Treatment and Prophylaxis of Seasonal Influenza. Updated October 23, 2026. Accessed October 27, 2026. https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-of-seasonal-influenza
[4] Australian Living Evidence Collaboration. Drug Treatments for People With Influenza Who Are Critically Ill: Australian Guideline. Version 1.2. Updated October 12, 2026. Accessed October 27, 2026. https://livingevidence.org.au/influenza/
[5] Bay P, Martin-Loeches I, Haudebourg AF, et al. How to manage antivirals in critically ill patients with influenza?. Clin Microbiol Infect. 2025;31(7):1157-1165. doi:10.1016/j.cmi.2025.04.002
[6] Gao Y, Guyatt G, Uyeki TM, et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;404(10454):753-763. doi:10.1016/S0140-6736(24)01307-2
[7] Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404. doi:10.1016/S2213-2600(14)70041-4

InpharmD's Answer GPT's Answer

Author:Naveed Aijaz, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Published evidence supports cranberry products for preventing urinary tract infections (UTIs) in women with recurrent UTIs, with systematic reviews also reporting benefit in children and individuals susceptible to UTIs following interventions. Current AUA/CUA/SUFU guidelines recommend offering cranberry as an option for prophylaxis in women with recurrent UTIs, classified as a moderate recommendation with Grade B evidence. However, individual trial results vary, and pooled evidence does not s...

A 2025 American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/CUA/SUFU) guideline update recommends that clinicians offer cranberry as an option for prophylaxis in women with recurrent urinary tract infections (UTIs), classified as a moderate recommendation with Grade B evidence. The guideline describes proanthocyanidins (PACs) as the proposed mediators of cranberry’s ability to prevent bacterial adhesion to the urothelium. A cited meta-analysis supports cranberry supplements standardized to at least 36 mg of PACs, reporting greater effectiveness in reducing UTI recurrence than products containing less than 36 mg; however, many commercial products lack documented validation of PAC dosage. Two recent randomized controlled trials involving 218 participants demonstrated reduced UTI rates with cranberry prophylaxis compared with placebo. Additionally, a 2024 systematic review and network meta-analys...

READ MORE→

A search of the published medical literature revealed 18 studies investigating the researchable question:

What is the most recent evidence regarding use of cranberry products and efficacy for UTI prevention?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Ackerman AL, Bradley M, D'Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 2026;215(1):3-12. doi:10.1097/JU.0000000000004723
[2] Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;11(11):CD001321. Published 2023 Nov 10. doi:10.1002/14651858.CD001321.pub7
[3] Moro C, Phelps C, Veer V, et al. Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2024;10(6):947-957. doi:10.1016/j.euf.2024.07.002
[4] Xiong Z, Gao Y, Yuan C, Jian Z, Wei X. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review. Front Nutr. 2024;11:1422121. Published 2024 Nov 28. doi:10.3389/fnut.2024.1422121
[5] Bryce MR, Bryce CJC. Cranberry products to reduce recurrence of urinary tract infections in older people: a narrative review. Asian Journal of Gerontology & Geriatrics. 2022;17(2):60-63. doi:10.12809/ajgg-2022-554-ra
[6] Xia JY, Yang C, Xu DF, Xia H, Yang LG, Sun GJ. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One. 2021;16(9):e0256992. Published 2021 Sep 2. doi:10.1371/journal.pone.0256992
[7] Fu Z, Liska D, Talan D, Chung M. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr. 2017;147(12):2282-2288. doi:10.3945/jn.117.254961
[8] Chughtai B, Thomas D, Howell A. Variability of commercial cranberry dietary supplements for the prevention of uropathogenic bacterial adhesion. Am J Obstet Gynecol. 2016;215(1):122-123. doi:10.1016/j.ajog.2016.03.046

InpharmD's Answer GPT's Answer

Author:zophia@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Available evidence identifies doxycycline as the best-supported alternative to benzathine penicillin G for latent syphilis in nonpregnant adults and adolescents, although noninferiority to penicillin has not been established. CDC guidelines list doxycycline 100 mg orally twice daily or tetracycline 500 mg orally four times daily, each for 28 days, as the only acceptable alternatives for late latent syphilis or syphilis of unknown duration in nonpregnant patients with penicillin allergy, witho...

The CDC’s 2021 Sexually Transmitted Infections Treatment Guidelines identify doxycycline 100 mg orally twice daily or tetracycline 500 mg orally four times daily, each for 28 days, as the only acceptable alternatives to penicillin for late latent syphilis or syphilis of unknown duration in nonpregnant patients with penicillin allergy. The guidelines do not designate either regimen as preferred and note that the effectiveness of alternatives to penicillin for latent syphilis has not been well documented, particularly among persons with HIV infection. These regimens require close clinical and serologic follow-up, with quantitative nontreponemal testing recommended at 6, 12, and 24 months. For clearly defined early latent syphilis, nonpregnant patients with penicillin allergy should respond to alternative antibiotics recommended for primary and secondary syphilis. Ceftriaxone might be effective for latent syphilis; however, its optimal dose and duration remain undefined, and treatment ...

READ MORE→

A search of the published medical literature revealed 3 studies investigating the researchable question:

What is the best alternate treatment for latent syphilis other than Penicillin g benzathine

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Centers for Disease Control and Prevention. Latent syphilis. Sexually Transmitted Infections Treatment Guidelines, 2021. Reviewed July 22, 2021. Accessed October 29, 2026.
[2] Callado GY, Gutfreund MC, Pardo I, et al. Syphilis treatment: systematic review and meta-analysis investigating nonpenicillin therapeutic strategies. Open Forum Infect Dis. 2024;11(4):ofae142. doi:10.1093/ofid/ofae142.
[3] Cvetkovic A, Erdman L, Johnstone R, Bartoszko JJ, Turner S, Mertz D. Effective Alternative Treatment Regimens for People With Infectious Syphilis: A Systematic Review and Network Meta-Analysis. Sex Transm Dis. 2026;53(9):626-636. doi:10.1097/OLQ.0000000000002341
[4] World Health Organization. WHO Guidelines for the Treatment of Treponema pallidum (Syphilis). World Health Organization; 2016. Accessed October 29, 2026. https://www.who.int/publications/i/item/9789241549714

InpharmD's Answer GPT's Answer

Author:Melissa Santibañez, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Limited evidence is available regarding tebipenem for non-urinary tract infections, with most clinical efficacy data involving the Japanese tebipenem pivoxil formulation (Orapenem). Clinical studies evaluating this formulation reported favorable outcomes in pediatric respiratory and otolaryngological infections and adult otolaryngological infections, including an overall clinical efficacy rate of 94.0% in pediatric patients with pneumonia, otitis media, or sinusitis. For the U.S. tebipenem pi...

A 2025 narrative review evaluated the antimicrobial activity, pharmacokinetics/pharmacodynamics, and clinical applications of oral penems and carbapenems, including tebipenem, for bacterial infections. For nonurinary indications, the review described clinical experience with tebipenem in pediatric respiratory tract infections using the Japanese formulation and pharmacokinetic studies demonstrating pulmonary epithelial lining fluid penetration and soft-tissue penetration in patients with diabetic foot infections using the U.S.-developed tebipenem pivoxil hydrobromide formulation. The authors also identified potential applications in intra-abdominal infections based on tebipenem's broad Gram-negative and anaerobic activity, although clinical trials evaluating its efficacy for this indication were lacking. [1]

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

Is there evidence for use of tebipenem in non-UTI indications?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Sayood S, Neuner E, Dumm R, Gandra S. The oral penems and carbapenems. Clin Microbiol Rev. 2025;38(4):e0004224. doi:10.1128/cmr.00042-24

InpharmD's Answer GPT's Answer

Author:Kevin Shin, PharmD, BCPS + InpharmD™ AI LEARN MORE 

In oncology patients receiving TPN/HPN, reported bloodstream infection incidence varies widely between stides. Several studies associate PN with increased catheter-related infection risk, but a hematologic malignancy study found no CLABSI association after adjustment. Among catheter routes, HPN data show potentially lower CRBSI with PICCs and ports than Hohn/tunneled catheters, but no direct enteral-versus-parenteral infection-rate comparisons were identified.

A search of the published medical literature revealed 7 studies investigating the researchable question:

Please review literature for incidence of bloodstream infections in oncology patients on TPN and data comparing infection rates with different routes of alimentation.

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

Why choose InpharmD™?

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


—   Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


—   Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


—   Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free